TTD Drug ID: DNC003717

Drug Information
Name	SC-44463
Indication	Not Available			Experimental
Structure	Click to save drug structure in 3D MOL format Click to save drug structure in 2D MOL format
InChI	1S/C19H29N3O5/c1-12(2)9-14(11-17(23)22-26)18(24)21-16(19(25)20-3) 10-13-5-7-15(27-4)8-6-13/h5-8,12,14,16,26H,9-11H2,1-4H3,(H,20,25) (H,21,24)(H,22,23)/t14-,16+/m1/s1
InChIKey	QYZPDCGWIJYZMN-ZBFHGGJFSA-N
Canonical SMILES	CC(C)CC(CC(=O)NO)C(=O)NC(CC1=CC=C(C=C1)OC)C(=O)NC
Isomeric SMILES	CC(C)C[C@H](CC(=O)NO)C(=O)N[C@@H](CC1=CC=C(C=C1)OC)C(=O)NC
Target	ADAMTS4			Inhibitor	[1]
	ADAMTS5			Inhibitor	[1]
	Matrix metalloproteinase 3			Inhibitor	[2]
	Matrix metalloproteinase 7			Inhibitor	[3]
	Matrix metalloproteinase 8			Inhibitor	[1]
	Matrix metalloproteinase 9			Inhibitor	[1]
	Matrix metalloproteinase-1			Inhibitor	[3]
	Matrix metalloproteinase-2			Inhibitor	[3]
Ref 1	J Med Chem. 2001 Oct 11;44(21):3347-50.Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivatives as potent, selective, and orally bioavailable aggrecanase inhibitors. To Reference
Ref 2	Bioorg. Med. Chem. Lett. 7(18):2331-2336 (1997) To Reference
Ref 3	J Med Chem. 2003 Jul 31;46(16):3514-25.A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers. To Reference

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.